A real-world observational study of treatment patterns and outcomes for patients with neuromyelitis optica spectrum disorders (NMOSD) treated with inebilizumab (UPLIZNA) in Europe First published 25/03/2024 Last updated 16/02/2026 EU PAS number:EUPAS1000000084 Study Planned